Semaglo-OB
Generic Name
Semaglutide 17 mg Injection
Manufacturer
Hypothetical Pharma Co.
Country
Global
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| semaglo ob 17 mg injection | ৳ 1,200.00 | N/A |
Description
Overview of the medicine
Semaglutide is a GLP-1 receptor agonist used for chronic weight management. It works by mimicking the effects of the natural GLP-1 hormone, which regulates appetite and food intake.
Uses & Indications
Dosage
Adults
Start with a lower dose (e.g., 0.25 mg weekly) and gradually titrate up over several weeks to the maintenance dose of 17 mg weekly, based on tolerability.
Elderly
No dose adjustment generally required, but monitor for adverse effects.
Renal_impairment
No dose adjustment for mild to moderate impairment; use with caution in severe impairment or end-stage renal disease (ESRD).
How to Take
Administer subcutaneously once weekly on the same day each week, at any time of day, with or without meals, in the abdomen, thigh, or upper arm. Rotate injection sites.
Mechanism of Action
Semaglutide binds to and activates the GLP-1 receptor, leading to increased insulin secretion, reduced glucagon secretion, delayed gastric emptying, and a reduction in appetite and calorie intake by acting on central nervous system pathways.
Pharmacokinetics
Onset
Blood glucose lowering effects seen within hours, weight loss effects gradually over weeks/months.
Excretion
Primarily urine (approx. 2/3) and feces (approx. 1/3) as metabolites and small amounts of intact drug.
Half life
Approximately 1 week (allowing once-weekly dosing).
Absorption
Slow absorption; peak plasma concentration after 1-3 days.
Metabolism
Metabolized through proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain, not primarily by cytochrome P450 enzymes.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of severe hypersensitivity to semaglutide or any component.
Drug Interactions
Oral medications
Semaglutide delays gastric emptying, potentially affecting absorption of orally administered drugs.
Insulin/Sulfonylureas
Increased risk of hypoglycemia.
Storage
Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. After first use, store at room temperature (below 30°C/86°F) or in a refrigerator for up to 6 weeks.
Overdose
Symptoms may include severe nausea, vomiting, or hypoglycemia. Supportive treatment, close monitoring for hypoglycemia, and symptomatic management.
Pregnancy & Lactation
Use in pregnancy only if potential benefit justifies potential risk. Discontinue at least 2 months before planned pregnancy. Unknown if excreted in human milk; avoid during breastfeeding.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of severe hypersensitivity to semaglutide or any component.
Drug Interactions
Oral medications
Semaglutide delays gastric emptying, potentially affecting absorption of orally administered drugs.
Insulin/Sulfonylureas
Increased risk of hypoglycemia.
Storage
Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. After first use, store at room temperature (below 30°C/86°F) or in a refrigerator for up to 6 weeks.
Overdose
Symptoms may include severe nausea, vomiting, or hypoglycemia. Supportive treatment, close monitoring for hypoglycemia, and symptomatic management.
Pregnancy & Lactation
Use in pregnancy only if potential benefit justifies potential risk. Discontinue at least 2 months before planned pregnancy. Unknown if excreted in human milk; avoid during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years unopened, store as directed.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Patented (until approx. 2031-2032 for original originator formulations)
Clinical Trials
Extensively studied in the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program, demonstrating significant weight reduction.
Lab Monitoring
- Blood glucose (if diabetic)
- Renal function
- Thyroid function (due to MTC risk)
Doctor Notes
- Emphasize lifestyle modification.
- Monitor for GI side effects and manage appropriately.
- Educate patients on proper injection technique and titration schedule.
Patient Guidelines
- Follow titration schedule carefully.
- Report severe gastrointestinal symptoms or signs of pancreatitis.
- Do not share pens.
Missed Dose Advice
If a dose is missed and the next scheduled dose is more than 2 days away, administer the missed dose as soon as possible. If the next scheduled dose is less than 2 days away, skip the missed dose and resume the regular schedule.
Driving Precautions
Unlikely to affect ability to drive or operate machinery, but monitor for hypoglycemia if used with insulin or sulfonylureas.
Lifestyle Advice
- Combine with a reduced-calorie diet and increased physical activity for optimal weight loss.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Semaglo-OB Brand
Other medicines available under the same brand name
Semaglo-OB
Solution for injection (pre-filled pen)
Semaglo-OB
Subcutaneous Injection
Semaglo-OB
Solution for subcutaneous injection
Semaglo-OB
Solution for Injection (Pre-filled Pen)